Details of the Drug

General Information of Drug (ID: DMMFWOJ)

• Drug Name: Probenecid
• Synonyms: Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Gout	FA25	Approved	[1], [2], [3]
Hyperuricaemia	5C55.Y	Approved	[1], [2], [3]

• Therapeutic Class: Uricosuric Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 285.36
  Topological Polar Surface Area (xlogp); 3.2
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.25 mL/min/kg [6]
  Elimination: 1.2% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 12 hours [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 58.52161 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.13% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.13 L/kg [6]
• Chemical Identifiers:
  Formula: C13H19NO4S
  IUPAC Name: 4-(dipropylsulfamoyl)benzoic acid
  Canonical SMILES: CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O
  InChI: InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
  InChIKey: DBABZHXKTCFAPX-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4911
  ChEBI ID: CHEBI:8426
  CAS Number: 57-66-9
  DrugBank ID: DB01032
  TTD ID: D0L7FM
  VARIDT ID: DR00232
  INTEDE ID: DR1341
  ACDINA ID: D00557

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 22 member 8 (SLC22A8)	TTTQR47	S22A8_HUMAN	Blocker	[8], [9]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 6 (SLC16A5)	DT3I124	MOT6_HUMAN	Substrate	[10]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[12]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) Main DME	DEYGVN4	UD11_HUMAN	Substrate	[13]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Probenecid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Decreased elimination of Probenecid caused by Cefuroxime mediated competitive inhibition of renal tubular secretion.	Acute bronchitis [CA42]	[46]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Probenecid and Glipizide.	Acute diabete complication [5A2Y]	[47]
Cefamandole	DMNEXZF	Moderate	Decreased elimination of Probenecid caused by Cefamandole mediated competitive inhibition of renal tubular secretion.	Anaerobic bacterial infection [1A00-1A09]	[46]
Cefotetan	DM07TX3	Moderate	Decreased elimination of Probenecid caused by Cefotetan mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Ceftizoxime	DM3VOGS	Moderate	Decreased elimination of Probenecid caused by Ceftizoxime mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Ticarcillin	DM4ME02	Minor	Decreased elimination of Probenecid caused by Ticarcillin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[48]
Cefoperazone	DM53PV8	Moderate	Decreased elimination of Probenecid caused by Cefoperazone mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Cefprozil	DM7DSYP	Moderate	Decreased elimination of Probenecid caused by Cefprozil mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Cefepime	DMHVWIK	Moderate	Decreased elimination of Probenecid caused by Cefepime mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Imipenem	DMI9FBP	Minor	Decreased elimination of Probenecid caused by Imipenem mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[49]
Meticillin	DMIKHN0	Minor	Decreased elimination of Probenecid caused by Meticillin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[48]
Cefpodoxime	DMJUNY5	Moderate	Decreased elimination of Probenecid caused by Cefpodoxime mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Cefadroxil	DMMC345	Moderate	Decreased elimination of Probenecid caused by Cefadroxil mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Bacampicillin	DMP54C7	Minor	Decreased elimination of Probenecid caused by Bacampicillin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[48]
Cefazolin	DMPDYFR	Moderate	Decreased elimination of Probenecid caused by Cefazolin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Cefonicid	DMTX2BH	Moderate	Decreased elimination of Probenecid caused by Cefonicid mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Cefradine	DMUNSWV	Moderate	Decreased elimination of Probenecid caused by Cefradine mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[50]
Cloxacillin	DMUTL7O	Minor	Decreased elimination of Probenecid caused by Cloxacillin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[48]
Amoxicillin	DMUYNEI	Minor	Decreased elimination of Probenecid caused by Amoxicillin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[48]
Cefoxitin	DMYTXVR	Moderate	Decreased elimination of Probenecid caused by Cefoxitin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[46]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Probenecid caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[51]
Ceftibuten	DMWV2AG	Moderate	Decreased elimination of Probenecid caused by Ceftibuten mediated competitive inhibition of renal tubular secretion.	Bronchitis [CA20]	[46]
Ardeparin	DMYRX8B	Minor	Increased risk of bleeding by the combination of Probenecid and Ardeparin.	Coronary thrombosis [BA43]	[52]
Benzylpenicillin	DMS9503	Minor	Decreased elimination of Probenecid caused by Benzylpenicillin mediated competitive inhibition of renal tubular secretion.	Discovery agent [N.A.]	[48]
Clonazepam	DMTO13J	Minor	Decreased metabolism of Probenecid caused by Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[53]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Probenecid caused by ITI-007 mediated inhibition of UGT.	Insomnia [7A00-7A0Z]	[54]
Quazepam	DMY4D87	Minor	Decreased metabolism of Probenecid caused by Quazepam.	Insomnia [7A00-7A0Z]	[53]
Estazolam	DMZGXUM	Minor	Decreased metabolism of Probenecid caused by Estazolam.	Insomnia [7A00-7A0Z]	[53]
Remimazolam	DMLVSYX	Minor	Decreased metabolism of Probenecid caused by Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[53]
Glycerol phenylbutyrate	DMDGRQO	Major	Decreased renal excretion of Probenecid caused by Glycerol phenylbutyrate.	Liver disease [DB90-DB9Z]	[55]
Phenylbutyrate	DMBHPDW	Major	Decreased renal excretion of Probenecid caused by Phenylbutyrate.	Metabolism inborn error [5C50]	[56]
Choline salicylate	DM8P137	Moderate	Antagonize the effect of Probenecid when combined with Choline salicylate.	Postoperative inflammation [1A00-CA43]	[57]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Probenecid caused by Selexipag mediated inhibition of UGT.	Pulmonary hypertension [BB01]	[58]
Salsalate	DM13P4C	Moderate	Antagonize the effect of Probenecid when combined with Salsalate.	Rheumatoid arthritis [FA20]	[57]
Cephapirin	DMV2JNY	Moderate	Decreased elimination of Probenecid caused by Cephapirin mediated competitive inhibition of renal tubular secretion.	Sepsis [1G40-1G41]	[50]
Deferiprone	DMS2M7O	Moderate	Decreased metabolism of Probenecid caused by Deferiprone mediated inhibition of UGT.	Thalassaemia [3A50]	[59]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Probenecid and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[47]
Doripenem	DM9UCJK	Moderate	Decreased elimination of Probenecid caused by Doripenem mediated competitive inhibition of renal tubular secretion.	Urinary tract infection [GC08]	[49]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carbonic acid disodium salt	E00199	10340	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Probenecid 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4357).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 007898.
• [4] BDDCS applied to over 900 drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
• [9] Interactions of organic anions with the organic cation transporter in renal BBMV. Am J Physiol. 1988 Jan;254(1 Pt 2):F56-61.
• [10] Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
• [11] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
• [12] Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22.
• [13] Modulation of 3'-azido-3'-deoxythymidine catabolism by probenecid and acetaminophen in freshly isolated rat hepatocytes. Biochem Pharmacol. 1991 Sep 12;42(7):1475-80.
• [14] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [15] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [16] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [17] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [18] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [19] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [20] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [21] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [22] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [23] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [24] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [25] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [26] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [27] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [28] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [29] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [30] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [31] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [32] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [33] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [34] Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
• [35] Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
• [36] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [37] Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
• [38] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [39] Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
• [40] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [41] Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
• [42] Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
• [43] Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
• [44] Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
• [45] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [46] Brown G, Zemcov SJ, Clarke AM "Effect of probenecid on cefazolin serum concentrations." J Antimicrob Chemother 31 (1993): 1009-11. [PMID: 8360120]
• [47] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [48] Allen MB, Fitzpatrick RW, Barratt A, Cole RB "The use of probenecid to increase the serum amoxycillin levels in patients with bronchiectasis." Respir Med 84 (1990): 143-6. [PMID: 2371437]
• [49] Product Information. Doribax (doripenem). Ortho McNeil Pharmaceutical, Raritan, NJ.
• [50] DiPiro JT, Welage LS, Levine BA, et al. Single-dose cefmetazole versus multiple dose cefoxitin for prophylaxis in abdominal surgery.?J Antimicrob Chemother. 1989;23 Suppl D:71-77. [PMID: 2722725]
• [51] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [52] Sanchez G "Enhancement of heparin effect by probenicid." N Engl J Med 292 (1975): 48. [PMID: 1109193]
• [53] Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
• [54] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [55] Product Information. Buphenyl (sodium phenylbutyrate). Horizon Pharma USA Inc, Northbrook, IL.
• [56] Goldbart A, Press J, Sofer S, Kapelushnik J "Near fatal acute colchicine intoxication in a child. A case report." Eur J Pediatr 159 (2000): 895-7. [PMID: 11131346]
• [57] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [58] Cerner Multum, Inc. "Australian Product Information.".
• [59] Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.